Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 84

Cited In for PubMed (Select 17502379)

1.

Hypoxia-inducible factor-1α restricts the anabolic actions of parathyroid hormone.

Frey JL, Stonko DP, Faugere MC, Riddle RC.

Bone Res. 2014 May 13;2:14005. doi: 10.1038/boneres.2014.5. eCollection 2014.

2.

MicroRNA-1908 functions as a glioblastoma oncogene by suppressing PTEN tumor suppressor pathway.

Xia X, Li Y, Wang W, Tang F, Tan J, Sun L, Li Q, Sun L, Tang B, He S.

Mol Cancer. 2015 Aug 12;14:154. doi: 10.1186/s12943-015-0423-0.

3.

Metabolic reprogramming in macrophages and dendritic cells in innate immunity.

Kelly B, O'Neill LA.

Cell Res. 2015 Jul;25(7):771-84. doi: 10.1038/cr.2015.68. Epub 2015 Jun 5. Review.

4.

Molecular mechanism of local drug delivery with Paclitaxel-eluting membranes in biliary and pancreatic cancer: new application for an old drug.

Bang S, Jang SI, Lee SY, Baek YY, Yun J, Oh SJ, Lee CW, Jo EA, Na K, Yang S, Lee DH, Lee DK.

Gastroenterol Res Pract. 2015;2015:568981. doi: 10.1155/2015/568981. Epub 2015 Apr 23.

5.

Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study.

Merchan JR, Qin R, Pitot H, Picus J, Liu G, Fitch T, Maples WJ, Flynn PJ, Fruth BF, Erlichman C.

Cancer Chemother Pharmacol. 2015 Mar;75(3):485-93. doi: 10.1007/s00280-014-2668-5. Epub 2015 Jan 3.

PMID:
25556030
6.

Therapeutic targeting of cellular metabolism in cells with hyperactive mTORC1: a paradigm shift.

Medvetz D, Priolo C, Henske EP.

Mol Cancer Res. 2015 Jan;13(1):3-8. doi: 10.1158/1541-7786.MCR-14-0343. Epub 2014 Oct 8.

PMID:
25298408
7.

Overnutrition, mTOR signaling, and cardiovascular diseases.

Jia G, Aroor AR, Martinez-Lemus LA, Sowers JR.

Am J Physiol Regul Integr Comp Physiol. 2014 Nov 15;307(10):R1198-206. doi: 10.1152/ajpregu.00262.2014. Epub 2014 Sep 24. Review.

PMID:
25253086
8.

Hypoxia promotes uveal melanoma invasion through enhanced Notch and MAPK activation.

Asnaghi L, Lin MH, Lim KS, Lim KJ, Tripathy A, Wendeborn M, Merbs SL, Handa JT, Sodhi A, Bar EE, Eberhart CG.

PLoS One. 2014 Aug 28;9(8):e105372. doi: 10.1371/journal.pone.0105372. eCollection 2014.

9.

δ-Tocotrienol oxazine derivative antagonizes mammary tumor cell compensatory response to CoCl2-induced hypoxia.

Ananthula S, Parajuli P, Behery FA, Alayoubi AY, Nazzal S, El Sayed K, Sylvester PW.

Biomed Res Int. 2014;2014:285752. doi: 10.1155/2014/285752. Epub 2014 Jul 22.

10.

Virus interactions with endothelial cell receptors: implications for viral pathogenesis.

Dalrymple NA, Mackow ER.

Curr Opin Virol. 2014 Aug;7:134-40. doi: 10.1016/j.coviro.2014.06.006. Epub 2014 Jul 24. Review.

11.

Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours.

Martin-Liberal J, Gil-Martín M, Sáinz-Jaspeado M, Gonzalo N, Rigo R, Colom H, Muñoz C, Tirado OM, García del Muro X.

Br J Cancer. 2014 Aug 26;111(5):858-65. doi: 10.1038/bjc.2014.370. Epub 2014 Jul 8.

12.

mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3.

Dodd KM, Yang J, Shen MH, Sampson JR, Tee AR.

Oncogene. 2015 Apr 23;34(17):2239-50. doi: 10.1038/onc.2014.164. Epub 2014 Jun 16.

PMID:
24931163
13.

Metabolic control of dendritic cell activation and function: recent advances and clinical implications.

Everts B, Pearce EJ.

Front Immunol. 2014 May 8;5:203. doi: 10.3389/fimmu.2014.00203. eCollection 2014. Review.

14.

mTOR in viral hepatitis and hepatocellular carcinoma: function and treatment.

Wang Z, Jin W, Jin H, Wang X.

Biomed Res Int. 2014;2014:735672. doi: 10.1155/2014/735672. Epub 2014 Apr 2. Review.

15.

First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium.

Harshman LC, Kroeger N, Rha SY, Donskov F, Wood L, Tantravahi SK, Vaishampayan U, Rini BI, Knox J, North S, Ernst S, Yuasa T, Srinivas S, Pal S, Heng DY, Choueiri TK.

Clin Genitourin Cancer. 2014 Oct;12(5):335-40. doi: 10.1016/j.clgc.2014.03.003. Epub 2014 Mar 15.

PMID:
24787966
16.

Hantavirus interferon regulation and virulence determinants.

Mackow ER, Dalrymple NA, Cimica V, Matthys V, Gorbunova E, Gavrilovskaya I.

Virus Res. 2014 Jul 17;187:65-71. doi: 10.1016/j.virusres.2013.12.041. Epub 2014 Jan 8.

17.

Rheb and mammalian target of rapamycin in mitochondrial homoeostasis.

Groenewoud MJ, Zwartkruis FJ.

Open Biol. 2013 Dec 18;3(12):130185. doi: 10.1098/rsob.130185. Review.

18.

Inhibition of protein kinase C delta attenuates allergic airway inflammation through suppression of PI3K/Akt/mTOR/HIF-1 alpha/VEGF pathway.

Choi YH, Jin GY, Li LC, Yan GH.

PLoS One. 2013 Nov 29;8(11):e81773. doi: 10.1371/journal.pone.0081773. eCollection 2013.

19.

hERG1 channels modulate integrin signaling to trigger angiogenesis and tumor progression in colorectal cancer.

Crociani O, Zanieri F, Pillozzi S, Lastraioli E, Stefanini M, Fiore A, Fortunato A, D'Amico M, Masselli M, De Lorenzo E, Gasparoli L, Chiu M, Bussolati O, Becchetti A, Arcangeli A.

Sci Rep. 2013 Nov 25;3:3308. doi: 10.1038/srep03308.

20.

Hypoxia induces permeability and giant cell responses of Andes virus-infected pulmonary endothelial cells by activating the mTOR-S6K signaling pathway.

Gavrilovskaya IN, Gorbunova EE, Mackow ER.

J Virol. 2013 Dec;87(23):12999-3008. doi: 10.1128/JVI.02103-13. Epub 2013 Sep 25.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk